Regulatory Lilly bags FDA okay for Wegovy pill rival orforglipron PharmaphorumEli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo RivalryNext: FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026